DOR/ISL was noninferior to BIC/FTC/TAF based on the percentage of patients with HIV-1 RNA levels 50 copies/mL at week 48. Topline data were announced from a phase 3 trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback